← Back to Screener
MBX Biosciences, Inc. Common Stock (MBX)
Price$30.65
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)0.50%
Price vs S&P 500 (4W)0.70%
VGM Score57.42
Market Capitalization$1.50B
All Metrics
Book Value / Share (Quarterly)$9.20
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.68
Price vs S&P 500 (YTD)-11.16%
EPS (TTM)$-2.21
10-Day Avg Trading Volume0.58M
EPS Excl Extra (TTM)$-2.21
EPS (Annual)$-2.38
ROI (Annual)-23.56%
Cash / Share (Quarterly)$9.25
ROA (Last FY)-22.58%
EBITD / Share (TTM)$-2.48
Cash Flow / Share (Annual)$-1.82
P/B Ratio3.42x
P/B Ratio (Quarterly)3.24x
Net Income / Employee (Annual)$-1,380,500
Net Interest Coverage (TTM)-347.47x
ROA (TTM)-23.58%
EPS Incl Extra (Annual)$-2.38
Current Ratio (Annual)24.62x
Quick Ratio (Quarterly)30.48x
3-Month Avg Trading Volume0.60M
52-Week Price Return147.41%
Revenue / Employee (TTM)$0
52-Week High$45.85
EPS Excl Extra (Annual)$-2.38
26-Week Price Return16.43%
Quick Ratio (Annual)24.31x
13-Week Price Return-10.19%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)30.79x
Enterprise Value$1.45B
Revenue / Employee (Annual)$0
Cash / Share (Annual)$8.32
3-Month Return Std Dev76.47%
Net Income / Employee (TTM)$-1,374,700
ROE (Last FY)-23.56%
EPS Basic Excl Extra (Annual)$-2.38
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.21
ROI (TTM)-24.50%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)119.20%
Year-to-Date Return-0.22%
5-Day Price Return-1.19%
EPS Normalized (Annual)$-2.38
Month-to-Date Return4.14%
EBITD / Share (Annual)$-2.68
EPS Basic Excl Extra (TTM)$-2.21
P/B Ratio (Annual)3.84x
Book Value / Share (Annual)$8.22
Price vs S&P 500 (13W)-19.93%
Beta1.84x
Revenue / Share (TTM)$0.00
ROE (TTM)-24.50%
52-Week Low$9.43
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.51est. -0.59
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.13
4.13
4.13
4.13
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
MBXMBX Biosciences, Inc. Common Stock | — | — | C | $30.65 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
MBX Biosciences is a clinical-stage biopharmaceutical company developing precision peptide therapies for endocrine and metabolic disorders. Its proprietary PEP platform optimizes pharmaceutical properties including extended duration, consistent drug exposure, and reduced dosing frequency compared to conventional peptides. The company's pipeline includes three candidates: MBX 2109, MBX 1416, and MBX 4291.